Treatment Groups | p-value | |||||||
---|---|---|---|---|---|---|---|---|
VR & RPT | MI & RPT | RPT alone | ||||||
N | % | N | % | N | % | |||
Hoehn and Yahr Stage at Baseline | Stage I | 5 | 25.00% | 3 | 15.00% | 3 | 15.00% | 0.82 |
Stage II | 8 | 40.00% | 9 | 45.00% | 7 | 35.00% | ||
Stage III | 7 | 35.00% | 8 | 40.00% | 10 | 50.00% | ||
Hoehn and Yahr Stage at 6th Week | Stage I | 7 | 35.00% | 4 | 20.00% | 4 | 20.00% | 0.472 |
Stage II | 8 | 40.00% | 9 | 45.00% | 6 | 30.00% | ||
Stage III | 5 | 25.00% | 7 | 35.00% | 10 | 50.00% | ||
Hoehn and Yahr Stage at 12th Week | Stage I | 10 | 50.00% | 5 | 25.00% | 4 | 20.00% | 0.121 |
Stage II | 7 | 35.00% | 10 | 50.00% | 7 | 35.00% | ||
Stage III | 3 | 15.00% | 5 | 25.00% | 9 | 45.00% | ||
Hoehn and Yahr Stage at 16th Week | Stage I | 9 | 45.00% | 4 | 20.00% | 3 | 15.00% | 0.098 |
Stage II | 8 | 40.00% | 11 | 55.00% | 8 | 40.00% | ||
Stage III | 3 | 15.00% | 5 | 25.00% | 9 | 45.00% |